Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality
| Autor: | Ayman F. Refaie, Khaled El-Dahshan, Mohamed A. Bakr, Yasser Elsayed Matter, Hanzada Mohamed El Maghrabi, Lionel Rostaing, Ahmed Yahia Elmowafy, Hazem Hamed Saleh, Gamal Shiha, M. Elbasiony |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Nephrology
Adult Cyclopropanes Male medicine.medical_specialty Cirrhosis Macrocyclic Compounds Proline Urology medicine.medical_treatment Lactams Macrocyclic 030232 urology & nephrology 030204 cardiovascular system & hematology Antiviral Agents 03 medical and health sciences 0302 clinical medicine Renal Dialysis Internal medicine medicine Humans Anilides Prospective Studies Sulfonamides Ritonavir business.industry virus diseases Valine Hepatitis C Hepatitis C Chronic Middle Aged medicine.disease digestive system diseases Ombitasvir Regimen Drug Combinations Treatment Outcome Paritaprevir Cytochrome P-450 CYP3A Inhibitors Egypt Female Hemodialysis Carbamates business medicine.drug |
| Zdroj: | International urology and nephrology. 51(9) |
| ISSN: | 1573-2584 |
| Popis: | New direct-acting antiviral drugs have become the corner-stone treatment for HCV infection: they show promising results with accepted side-effects and low dropout rates. One of the available regimens is paritaprevir/ombitasvir/ritonavir (PTV/OMV/RTV). Our aim was to study the efficacy and safety of this drug regimen among HCV-positive hemodialysis patients. This prospective single-center study was performed in the Urology and Nephrology Center, Mansoura University, Egypt. Ninety-six maintenance hemodialysis patients were screened for HCV antibodies. Positive results were found in 46 patients (47.9%). HCV PCR was assessed in all HCV-antibody-positive patients; positive results were found positive for 38 (82%); all patients were HCV genotype 4. Four patients were excluded due to advanced liver cirrhosis, liver malignancy, or metastatic breast cancer. Thirty-four patients were prescribed PTV/OMV/RTV for 3 months to treat HCV. Mean age was 43.2 ± 11.9 years. Most patients were male (67.6%). There was a rapid response to treatment: HCV PCR became negative by 4 weeks after starting treatment. By 12 and 24 weeks post-DAA therapy, there was a sustained viral response (SVR 12, SVR 24) in 100% of patients with improved liver-enzyme levels. The PTV/OMV/RTV regimen was safe and effectively treated Egyptian HCV-positive genotype-4 hemodialysis patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink